- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00820482
Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.
September 17, 2009 updated by: Instituto Valenciano de Infertilidad, IVI VALENCIA
A Prospective, Randomized, Controlled Trial Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination: Ovarian Response and Clinical Outcomes.
The present study aims to elucidate if the FSH and LH activity contained in hMG preparations is comparable to the recombinant FSH and LH administration in a 1:1 ratio.
The mean outcome is the corresponding ovarian response in terms of oestradiol increase during stimulation and number of mature follicles the day of hCG administration.
The patients will be included and randomized into two groups and stimulated either by HMG injections started on day 3 at a dose of 75 IU every day and fixed for the first 5 days, and in the second group, rFSH and rLH injections be started on day 3 at a dose of 75 UI/day of rFSH + 75UI/day of rLH.
Serum estradiol levels will be measured on stimulation day 1, day 6 and the day of hCG injection.
All follicles greater than 14 mm of diameter will be recorded on hCG day Intrauterine insemination is performed during two consecutive days starting the day after the human chorionic gonadotrophin (Ovitrelle) injection.
Secondary outcomes are Days of stimulation, Total doses of gonadotrophins administrated, Clinical pregnancy , Ongoing pregnancy and Miscarriage rate, and Cancellation rate.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Valencia, Spain, 46117
- IVI Valencia
-
Valencia, Spain, 4
- IVI Valencia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 39 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Esterility > 1 year duration
- < 39 years old
- REM > 3 millions/ml
- 1 or 2º IUI cycle
Exclusion criteria:
- Ovarian policystic syndrome
- Severe Endometriosis
- Uterine disease (polyps, myomas, intracavitarios, malformations…)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
|
75 UI/day of Hp-hMG (Menopur®)
|
Experimental: Group B
75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
|
75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The present study aims to elucidate if the FSH and LH activity contained in hMG preparations is comparable to the recombinant FSH and LH administration in proporción 1:1. Mean outcome: - Ovarian response according to the protocol used.
Time Frame: one month
|
one month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcomes: - Days of stimulation - Total doses of gonadotrophins administrated - Clinical pregnancy , ongoing pregnancy and miscarriage rate - Cancellation rate
Time Frame: one cycle
|
one cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Elena Labarta, MD, IVI Valencia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
January 8, 2009
First Submitted That Met QC Criteria
January 8, 2009
First Posted (Estimate)
January 12, 2009
Study Record Updates
Last Update Posted (Estimate)
September 18, 2009
Last Update Submitted That Met QC Criteria
September 17, 2009
Last Verified
September 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VLC- EL-0106-307-9
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Stimulation Preceding Intrauterine Insemination
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
Gynuity Health ProjectsStanford UniversityCompletedEmbryo Transfer | Intrauterine Insemination (IUI)United States
-
Mayo ClinicCompletedIntrauterine InseminationUnited States
-
Peking University Third HospitalCompletedInfertility | Intrauterine InseminationChina
-
Sohag UniversityUnknownIntrauterine Insemination
-
Ankara UniversityCompleted
-
Clinique OvoCompletedInfertility | Intrauterine Insemination | ReproductionCanada
-
Mansoura UniversityCompletedInfertility | Polycystic Ovarian Syndrome | Intrauterine InseminationEgypt
-
Peking University Third HospitalThe 1st Affiliated Hospital of Anhui Medical University; The 2nd Affiliated... and other collaboratorsRecruitingUnexplained Infertility | Intrauterine InseminationChina
-
Suleyman Demirel UniversityNot yet recruitingAnxiety | Patient Satisfaction | Virtual Reality | Intrauterine Insemination (IUI)
Clinical Trials on Menopur®, Ferring
-
Hospital de Clinicas de Porto AlegreCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompletedSensitivity (Hyper); Gastrointestinal
-
Prof Dr Jan TackCompletedEsophageal Motility DisordersBelgium
-
Peter Kovacs MDRecruitingInfertility | Ovarian DysfunctionHungary
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedInfertilityKorea, Republic of
-
Ferring PharmaceuticalsCompleted
-
LG Life SciencesCompleted
-
Ferring PharmaceuticalsCompleted